Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Freenome, Inc. Common stock

FRNM

Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.

Last trade $9.98
Day change -$0.115 (-1.14%)
Day range $9.83 – $10.80
Volume 287,556
Market cap $1.13B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.13B
Price / earnings
19×
Price / book
2.34×
Price / sales
6.13×
EV / sales
5.15×
EV / EBITDA
11.14×

Profitability

Earnings per share
$0.53
Return on assets
8.07%
Return on equity
12.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
12.73×
Quick ratio
12.68×
Cash ratio
4.98×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$74.26M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FRNM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026
Revenue$183.49M
Cost of revenue$478K
Gross profit$183.01M
Selling, general and administrative$44.63M
Research and development$68.42M
Total operating expenses$113.05M
Operating income$69.97M
Interest expense-$1.19M
Income before taxes$60.11M
Income taxes$0
Net income$60.11M
Net income attributable to common shareholders$60.11M
EBITDA$88.26M
Basic earnings per share$0.60
Diluted earnings per share$0.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Freenome announced improved validation data for its updated SimpleScreen CRC blood-based colorectal cancer screening test, demonstrating 18.2% sensitivity for advanced precancerous lesions (up from 13.7%) and 80.4% sensitivity for colorectal cancer detection at 90% specificity. The FDA-approved test, commercialized by partner Abbott Cancer Diagnostics, will be presented at ACG 2026 Annual Meeting in Nashville.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.